EQRx, Inc. (NASDAQ:EQRX) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET

Company Participants

Neil Swami - Head, IR

Melanie Nallicheri - President and CEO

Jami Rubin - CFO

Eric Hedrick - Chief Physician Executive

Conference Call Participants

Eric Percher - Nephron Research

Chris Shibutani - Goldman Sachs

Operator

Good day. And thank you for standing by. Welcome to the EQRx Q2 2022 Earnings Conference Call.

At this time, all participants in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator instructions] Please be advised that today's conference is being recorded.

And I'd now like to hand the conference over to your speaker today, Mr. Neil Swami, Head of Investor Relations. Mr. Swami, please go ahead.

Neil Swami

Thank you, operator and good morning, everyone. Earlier today, we issued a press release providing an overview of our second quarter 2022 financial results and our recent corporate progress. A copy of this release and presentation to accompany this call are available on the investor relations section of our website at investors.eqrx.com.

Joining me on the call this morning are Melanie Nallicheri, President and Chief Executive Officer; Jami Rubin, Chief Financial Officer, and Dr. Eric Hedrick, Chief Physician Executive.

Before we get started, I would like to remind everyone that, some of the statements that we make on this call and information presented in the slide deck include forward-looking statements as outlined on Slide 2. Actual events and results could differ materially from those expressed or implied by any forward-looking statements, as a result of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and other future filings that we may make with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements and EQRx disclaimed any obligation to update such statements.

I will now turn the call over to Melanie.

Melanie Nallicheri

Thank you, Neil. Good morning, everyone. And thank you for joining us for our quarterly investor conference call. Slide 3 is a reminder of our mission; to improve health for all with great, innovative, affordable medicines. This is increasingly relevant as we've seen the US Senate debate and advance prescription drug pricing reform legislation this week.

EQRx is creating a market-based approach to bring down prices and address inequitable access for patients. We believe our approach will increase competition, foster biomedical innovation, create savings for healthcare systems, and most importantly, provide population level access to innovative therapies in the US and around the world.